Longevity of protective immune responses induced by a split influenza A (H7N9) vaccine mixed with MF59 adjuvant in BALB/c mice
| Autor: | Wei Yao, Xiaoxin Wu, Dong-Shan Yu, Lanjuan Li, Hangping Yao, Xiangyun Lu, Linfang Cheng, Haibo Wu, Frederick Wang, Honglin Chen, Tianhao Weng, Huilin Ou, Nanping Wu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Influenza vaccine medicine.medical_treatment MF59 immunogenicity medicine.disease_cause Virus H7N9 03 medical and health sciences 0302 clinical medicine medicine 030212 general & internal medicine biology business.industry Immunogenicity Antibody titer protective immune responses Virology Influenza A virus subtype H5N1 030104 developmental biology adjuvant vaccine Oncology Immunology biology.protein business Adjuvant Neuraminidase Research Paper |
| Zdroj: | Oncotarget |
| ISSN: | 1949-2553 |
| Popis: | // Huilin Ou 1,* , Wei Yao 2,* , Dongshan Yu 1,* , Tianhao Weng 1 , Frederick X.C. Wang 3 , Xiaoxin Wu 1 , Haibo Wu 1 , Linfang Cheng 1 , Xiangyun Lu 1 , Nanping Wu 1 , Honglin Chen 4 , Lanjuan Li 1 and Hangping Yao 1 1 State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China 2 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., Hangzhou, China 3 Department of Bioengineering, Erik Jonsson School of Engineering and Computer Science, The University of Texas at Dallas, Dallas, Texas, USA 4 State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong, China * These authors have contributed equally to this article Correspondence to: Hangping Yao, email: // Lanjuan Li, email: // Keywords : H7N9, adjuvant vaccine, MF59, immunogenicity, protective immune responses Received : May 26, 2017 Accepted : July 29, 2017 Published : August 08, 2017 Abstract The influenza virus is a serious threat to public health worldwide. A novel avian influenza A (H7N9) virus with a mortality rate of approximately 30% has been identified as an unusually dangerous virus for humans by the World Health Organization. Pathogenic H7N9 continue to represent a public health concern, and several candidate vaccines are currently in development. We generated candidate H7N9 vaccine strains using reverse genetics, consisting of hemagglutinin and neuraminidase genes derived from a human H7N9 virus and the remaining genes from the PR8 (A/PuertoRico/8/34 (H1N1)) virus. This H7N9 vaccine exhibited superior efficacy when combined with MF59 compared to other adjuvants. Immunized BALB/c mice were followed to determine the duration of the protective immune response. Antibody levels decreased to between one-half and one-eighth of the peak values four months after the final dose of the vaccine. Previously vaccinated mice received an A/Zhejiang/DTID-ZJU01/2013 H7N9 challenge six months post-vaccination, and all remained protected. We also verified that MF59 enhanced the HI, MN, and IgG antibody titers to influenza antigens. The humoral immune response and Th2 cytokine production following influenza challenge was potently induced in the animals that received the split vaccine. Therefore, the split H7N9 influenza vaccine with the MF59 adjuvant could effectively induce antibody production and protect mice from H7N9 virus challenge even after six months. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|